The Midwest hospital system aims to embed genetic testing into everyday care for heart disease and discover new genetic risk ...

The company's outlook for the rest of the year was rosier than in the previous quarter, when it announced cost-cutting plan ...

The agency said the move could halve the time it takes for biosimilars to enter the market, drive competition, and reduce ...

This year, BMS partnered to develop a PD-L1 and VEGF bispecific antibody and has acquired the rights to a new radiopharmaceutical asset.

The clinical hold follows Intellia's disclosure that it paused dosing in two Phase III trials after a patient experienced a serious adverse event.

The firm is betting that treatments from new acquisitions, including its recent $12B bid for Avidity Biosciences, will ...

Patients on a perioperative Keytruda regimen saw a 30 percent reduction in the risk of recurrence, progression, or death versus the control arm.

The hospital system is betting the move will give it better control over turnaround time and allow it to be more "nimble" in ...

The financing will allow the company to build commercial-grade manufacturing capabilities and make regulatory preparations in the US.

A man with neurofibromas who didn't know he's been clinically diagnosed with NF1, learns he harbors a deeply intronic, likely ...

In the small first-in-human study, AB-1002 showed an encouraging safety profile and early signs of efficacy, investigators ...

The investigator-initiated study will evaluate Create's MT-302 plus chemo with or without standard immunotherapy and anti-HER2 therapy in the first-line setting.